Humacyte Inc.

AI Score

0

Unlock

4.24
0.12 (2.91%)
At close: Jan 15, 2025, 10:23 AM
undefined%
Bid 4.23
Market Cap 545.55M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.34
PE Ratio (ttm) -3.16
Forward PE n/a
Analyst Buy
Ask 4.25
Volume 746,853
Avg. Volume (20D) 4,907,577
Open 4.20
Previous Close 4.12
Day's Range 4.03 - 4.24
52-Week Range 2.48 - 9.97
Beta undefined

About HUMA

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without i...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 1, 2020
Employees 183
Stock Exchange NASDAQ
Ticker Symbol HUMA

Analyst Forecast

According to 8 analyst ratings, the average rating for HUMA stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 230.19% from the latest price.

Buy 75.00%
Hold 12.50%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Humacyte Inc. is scheduled to release its earnings on Mar 21, 2025, before market opens.
Analysts project revenue of $420.00K, reflecting a n/a YoY growth and earnings per share of -0.26, making a 8.33% increase YoY.
3 weeks ago · Source
+34.1%
Humacyte shares are trading higher after the compa... Unlock content with Pro Subscription
2 months ago · Source
+3.5%
Humacyte shares are trading higher. BTIG and TD Cowen reiterated Buy ratings on the stock.